Karyopharm Therapeutics Inc.: 10-Q filed 2014-08-07
What Karyopharm Therapeutics Inc. reported in its quarterly report filed 2014-08-07 (fiscal Q2 2014): 26 published measures, 66 facts as tagged in accession 0001104659-14-057869.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-08-07
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001104659-14-057869 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Karyopharm Therapeutics Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 137,679,000 | USD | |
| At 2013-12-31 | 158,226,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 5,999,000 | USD | |
| At 2013-12-31 | 3,292,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 131,680,000 | USD | |
| At 2013-12-31 | 154,934,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 132,307,000 | USD | |
| At 2013-12-31 | 155,974,000 | USD | |
| At 2013-06-30 | 17,667,000 | USD | |
| At 2012-12-31 | 391,000 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 449,000 | USD | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 604,000 | USD | |
| At 2013-12-31 | 240,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 6,734,000 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 446,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -16,448,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -30,159,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -6,870,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -12,481,000 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 135,283,000 | USD | |
| At 2013-12-31 | 157,956,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 5,647,000 | USD | |
| At 2013-12-31 | 3,292,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 3,456,000 | USD | |
| At 2013-12-31 | 1,740,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 16,469,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 30,352,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 7,003,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 12,847,000 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 13,159,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 24,138,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 6,060,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 11,025,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 29,720,422 | shares | |
| At 2013-12-31 | 29,587,258 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 224,371,000 | USD | |
| At 2013-12-31 | 217,500,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 1,039,000 | USD | |
| At 2013-12-31 | 590,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 435,000 | USD | |
| At 2013-12-31 | 350,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 1,392,000 | USD | |
| At 2013-12-31 | 30,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 151,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 2,003,000 | USD | |
| At 2013-12-31 | 1,168,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 2,976,000 | USD | |
| At 2013-12-31 | 1,982,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -16,431,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -30,125,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -6,869,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -12,480,000 | USD | 181 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -16,431,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -30,125,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -6,869,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -12,480,000 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 3,310,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 6,214,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 943,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,822,000 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 17,000 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 34,000 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 1,000 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,000 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 1,685,000 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 652,000 | USD | 181 |
Inspect the source
- Entity
- Karyopharm Therapeutics Inc. / CIK 0001503802
- Captured
- 2026-09-20T09:12:00.482Z
- SEC response SHA-256
fc01ae30f39685ae62660019ff98663a0f1e1ff79fbb8ba679388fab92736423
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001503802.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))